EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the LRRK2 G2019S Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy

Keelan Jagaran, Moganavelli Singh

Frontiers in Bioscience-Elite · 2025

DOI: 10.31083/fbe44344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Elite, 2025. Verfasst von Keelan Jagaran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, 4000 Durban, South Africa. Hauptthemen laut MEDLINE: Parkinson Disease, Nanoparticles, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, RNA, Small Interfering. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, South Africa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a progressive neurodegenerative disorder with which the leucine-Rich repeat kinase 2 glycine 2019 serine (LRRK2 G2019S) mutation is strongly associated. This mutation elevates kinase activity, disrupts mitochondrial function, increases reactive oxygen species (ROS) production, and impairs DNA repair mechanisms, all of which contribute to the pathogenesis of PD. Thus, addressing these pathological features through targeted delivery systems holds promise for more effective therapies.

Methods

This study aimed to investigate the use of Ginkgo biloba leaf extract (EGB) to synthesize sphingomyelin-cholesterol solid lipid nanoparticles (SLNPs) functionalized with poly-L-lysine (EGB–PLL–SLNPs) for siRNA delivery targeting the LRRK2 G2019S mutation. SLNPs suspended in water (H₂O–PLL–SLNPs) served as the comparator. In vitro assays were conducted using either wild-type or LRRK2 G2019S-transformed SH-SY5Y and HEK293 cells. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed to evaluate the cytotoxicity of the SLNPs and nanocomplexes; meanwhile, flow cytometry was used to assess caspase 3/7 activity, mitochondrial membrane potential, DNA damage, and ROS levels.

Results

Treatment with EGB–PLL–SLNPs significantly improved mitochondrial health, reducing depolarized and dead cells and enhancing overall cell viability. ROS levels, DNA damage and kinase activity were significantly decreased compared to the control H₂O–PLL–SLNPs.

Conclusion

The enhanced therapeutic outcomes observed with the EGB–PLL–SLNPs can be attributed to the bioactive compounds in EGB, particularly the flavonoids and terpenoids, such as quercetin and kaempferol. These molecules play crucial roles in stabilizing mitochondrial membranes, facilitating ATP synthesis, and regulating genes linked to mitochondrial biogenesis. The interaction between EGB and siRNA to mediate gene silencing provides a multifaceted approach to counteracting PD pathophysiology. This study demonstrates that EGB–PLL–SLNPs offer superior gene silencing and cytoprotective effects compared to conventional formulations. The integration of plant-based bioactives with nanomedicine enhances therapeutic delivery and efficacy, positioning biosynthesized PLL–SLNPs as a promising strategy for treating Parkinson's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseNanoparticlesLeucine-Rich Repeat Serine-Threonine Protein Kinase-2RNA, Small InterferingGenetic TherapyHumansMutationGinkgo bilobaGene Therapy AgentsLipidsProtein Serine-Threonine KinasesPlant ExtractsHEK293 CellsReactive Oxygen Species

Stichwörter der Autor:innen

Ginkgo bilobaLRRK2 G2019SParkinson's diseaseSLNPsgene therapynanomedicinesiRNA

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2RNA, Small InterferingLRRK2 protein, humanLipidsProtein Serine-Threonine KinasesPlant ExtractsReactive Oxygen Species

Autor:innen und Institutionen

  • Nano-Gene and Drug Delivery Laboratory, Discipline of Biochemistry, University of KwaZulu-Natal, 4000 Durban, South Africa.

Förderung

  • National Research Foundation, South Africa

Zitieren

APA

Jagaran, K., & Singh, M. (2025). Targeting the LRRK2 G2019S Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy. Frontiers in Bioscience-Elite. https://doi.org/10.31083/fbe44344

Vancouver

Jagaran K, Singh M. Targeting the LRRK2 G2019S Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy. Frontiers in Bioscience-Elite. 2025. doi:10.31083/fbe44344

BibTeX
@article{Jagaran2025,
  author = {Jagaran, Keelan and Singh, Moganavelli},
  title = {Targeting the LRRK2 G2019S Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy},
  journal = {Frontiers in Bioscience-Elite},
  year = {2025},
  doi = {10.31083/fbe44344}
}
Kostenlos starten →